BRPI0710483A8 - composições e kits úteis para o tratamento de doenças respiratórias - Google Patents

composições e kits úteis para o tratamento de doenças respiratórias

Info

Publication number
BRPI0710483A8
BRPI0710483A8 BRPI0710483A BRPI0710483A BRPI0710483A8 BR PI0710483 A8 BRPI0710483 A8 BR PI0710483A8 BR PI0710483 A BRPI0710483 A BR PI0710483A BR PI0710483 A BRPI0710483 A BR PI0710483A BR PI0710483 A8 BRPI0710483 A8 BR PI0710483A8
Authority
BR
Brazil
Prior art keywords
compositions
treatment
respiratory diseases
salt
kits useful
Prior art date
Application number
BRPI0710483A
Other languages
English (en)
Inventor
K Anness Daren
William Gledhill Douglas
Rose Costeines Elaine
Ekanth Khanolkar Jayant
Lee Martin Kelly
Ramji Niranjan
R Iyer Radhika
Elaine Criss Susan
Edward Huetter Thomas
Original Assignee
Ekanth Khanolkar Jayant
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48805455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0710483(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/408,299 external-priority patent/US10022339B2/en
Application filed by Ekanth Khanolkar Jayant, Procter & Gamble filed Critical Ekanth Khanolkar Jayant
Publication of BRPI0710483A2 publication Critical patent/BRPI0710483A2/pt
Publication of BRPI0710483A8 publication Critical patent/BRPI0710483A8/pt
Publication of BRPI0710483B1 publication Critical patent/BRPI0710483B1/pt
Publication of BRPI0710483B8 publication Critical patent/BRPI0710483B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<b>composições e kits úteis para o tratamento de doenças respiratorias<d>. a presente invenção refere-se a um dispositivo transparente no qual está contida uma composição, em que a dita composição líquida compreende um ativo farmacêutico selecionado do grupo consistindo em fenilefrina, em suas formas isentas de sal e com adição de sal, e misturas das mesmas. são, também, descritos kits que compreendem: uma composição contida em um dispositivo, em que a dita composição líquida compreende um ativo farmacêutico selecionado do grupo consistindo em fenilefrina, em suas formas isentas de sal e com adição de sal, e misturas das mesmas.
BRPI0710483A 2006-04-21 2007-04-20 dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e kits úteis para o tratamento de doenças respiratórias BRPI0710483B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/408,299 2006-04-21
US11/408,299 US10022339B2 (en) 2006-04-21 2006-04-21 Compositions and methods useful for treatment of respiratory illness
US11/657,860 2007-01-25
US11/657,860 US20070249727A1 (en) 2006-04-21 2007-01-25 Compositions and kits useful for treatment of respiratory illness
PCT/IB2007/051470 WO2007122581A2 (en) 2006-04-21 2007-04-20 Compositions and kits of phenylephrine

Publications (4)

Publication Number Publication Date
BRPI0710483A2 BRPI0710483A2 (pt) 2011-08-16
BRPI0710483A8 true BRPI0710483A8 (pt) 2018-01-02
BRPI0710483B1 BRPI0710483B1 (pt) 2019-07-30
BRPI0710483B8 BRPI0710483B8 (pt) 2021-05-25

Family

ID=48805455

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710483A BRPI0710483B8 (pt) 2006-04-21 2007-04-20 dispositivo compreendendo composições com fenilefrina, cloridrato de fenilefrina, bromidrato de fenilefrina, e misturas das mesmas e kits úteis para o tratamento de doenças respiratórias

Country Status (11)

Country Link
US (6) US20070249727A1 (pt)
EP (1) EP2046289B1 (pt)
JP (1) JP5362549B2 (pt)
CN (1) CN101631539A (pt)
AU (1) AU2007242419B2 (pt)
BR (1) BRPI0710483B8 (pt)
CA (1) CA2650036C (pt)
ES (1) ES2454967T3 (pt)
MX (1) MX2008013257A (pt)
PL (1) PL2046289T3 (pt)
WO (1) WO2007122581A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070254027A1 (en) * 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
RU2527680C2 (ru) * 2009-06-04 2014-09-10 Альк Аг Стабилизированная композиция, содержащая по меньшей мере одно адренергическое соединение
MX389960B (es) * 2009-10-12 2025-03-20 Boehringer Ingelheim Vetmedica Gmbh Recipientes para composiciones que comprenden meloxicam.
CA2791805A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CA2899492C (en) * 2013-02-13 2019-09-17 The Procter & Gamble Company Anise flavored medication
TR201618030T2 (tr) * 2014-08-14 2018-09-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Tadı düzeltilmiş parasetamol formülasyonları.
US11213480B1 (en) 2015-08-06 2022-01-04 Hikma Pharmaceuticals International Limited Phenylephrine hydrochloride ready-to-use solution
WO2018183082A1 (en) 2017-03-27 2018-10-04 Paracap Pharmaceutical Llc Formulations containing expectorants or decongestants
GR1009541B (el) * 2018-02-26 2019-06-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν μελατονινη
US11911517B2 (en) 2018-05-16 2024-02-27 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN111588694A (zh) * 2020-05-15 2020-08-28 北京博达绿洲医药科技研究有限公司 包含盐酸去氧肾上腺素的液体组合物及其制剂和用途
WO2023129926A1 (en) * 2021-12-29 2023-07-06 Baxter International Inc. Phenylephrine premix formulations and uses thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395495A (en) 1932-06-04 1933-07-20 Dunlop Rubber Co A new or improved method of storing, under pressure, tennis or other inflated balls
GB836747A (en) 1957-07-31 1960-06-09 Upjohn Co Improvements in or relating to steroidal compounds and compositions and the preparation thereof
GB895495A (en) 1960-01-20 1962-05-02 Boots Pure Drug Co Ltd Amino-acetamidoximes and their preparation
US3169092A (en) 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3293045A (en) 1963-10-18 1966-12-20 Pfizer & Co C Increasing the flavor strength of anethole, cinnamaldehyde and methyl salicylate with maltol
GB1121358A (en) 1965-10-21 1968-07-24 Bristol Myers Co Aerosol manufacture
US3480185A (en) 1966-06-20 1969-11-25 Johnson & Johnson Charged effervescing agent and medicament dispensing metering valve-actuated aerosol container producing a dose of medicament and carbonation in water
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4049803A (en) 1976-04-26 1977-09-20 Bristol-Myers Company Augmentation of blood levels of aspirin
JPH0780760B2 (ja) * 1986-07-28 1995-08-30 ライオン株式会社 安定化されたフエニレフリン系液剤
DE3868793D1 (de) 1987-09-04 1992-04-09 Procter & Gamble Psyllium enthaltende fuellungszusammenstellungen.
ES2045748T3 (es) 1989-03-16 1994-01-16 Procter & Gamble Galletas horneadas con alto contenido en fibra, que contienen psyllium.
JP3256997B2 (ja) * 1990-08-30 2002-02-18 千寿製薬株式会社 安定な水性製剤
US5178025A (en) 1990-08-31 1993-01-12 Innovative Medical Engineering, Inc. Tiltable lift seat devices
US5196436A (en) 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
US5296209A (en) 1992-01-17 1994-03-22 Colgate Palmolive Company Pet chew product having oral care properties
EP0662840A1 (en) * 1992-10-09 1995-07-19 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
US5480674A (en) 1993-06-25 1996-01-02 Firmenich Incorporated Flavor composition for an oral electrolyte rehydration solution
JP3643604B2 (ja) 1993-09-17 2005-04-27 セイコーインスツル株式会社 内面研削盤における研削方法
JP3021312B2 (ja) * 1994-03-15 2000-03-15 千寿製薬株式会社 プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤
GB9422571D0 (en) 1994-11-09 1995-01-04 Whitehall Lab Ltd Haemorrihoidal compositions and method of use
JPH09286726A (ja) 1996-04-18 1997-11-04 Takeda Chem Ind Ltd 経口液剤
JPH09286723A (ja) 1996-04-19 1997-11-04 Takeda Chem Ind Ltd 改善された経口液剤
JPH09286724A (ja) 1996-04-19 1997-11-04 Takeda Chem Ind Ltd 経口用安定液剤
US5660833A (en) 1996-06-05 1997-08-26 Medenica; Rajko D. Anti-tussive composition
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
JPH10167988A (ja) 1996-10-09 1998-06-23 Takeda Chem Ind Ltd 経口液剤
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DK1051155T3 (da) 1998-01-30 2002-09-16 Novartis Consumer Health Sa Nasale opløsninger
JP3262091B2 (ja) * 1998-12-25 2002-03-04 ライオン株式会社 洗眼剤組成物、洗眼剤組成物のべたつき感を解消する方法及び洗眼用セット
US20020082307A1 (en) 1999-01-11 2002-06-27 Dobrozsi Douglas Joseph Compositions having improved stability
US6287597B1 (en) * 1999-03-12 2001-09-11 Carter-Wallace, Inc. Antihistaminic/decongestant compositions
US6218428B1 (en) * 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
JP4737911B2 (ja) 2000-05-17 2011-08-03 千寿製薬株式会社 点眼剤
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
JP2002212107A (ja) 2001-01-22 2002-07-31 Taisho Pharmaceut Co Ltd 局所適用組成物
US20030026826A1 (en) 2001-07-31 2003-02-06 Cherukuri Subraman Rao Sugar-free chewy products and protein-based chewy products and methods for making the same
NZ530889A (en) 2001-07-31 2005-03-24 Wyeth Corp Use of sucralose as a sweetening agent combined with pH modulation of chemical formulations generates enhanced taste-masking effects
JP2003063962A (ja) * 2001-08-29 2003-03-05 Taisho Pharmaceut Co Ltd 鼻閉症用組成物
US20030083354A1 (en) 2001-10-26 2003-05-01 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20040132827A1 (en) * 2001-10-26 2004-07-08 Pediamed Pharmaceuticals, Inc. Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions
AU2002352974A1 (en) * 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
US20030170371A1 (en) 2002-01-10 2003-09-11 Cargill, Inc. High fat/fiber composition
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
AU2003301654A1 (en) 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
US20050214349A1 (en) 2002-10-30 2005-09-29 Li Nie Extruded gluten based pet chew bodies
US20060193959A1 (en) 2002-10-30 2006-08-31 Li Nie Low calorie injection molded starch-based pet chew bodies
US20040259955A1 (en) * 2002-11-08 2004-12-23 Boehringer Ingelheim International Gmbh New pharmaceutical compositions containing ambroxol and isopropamide iodide
DE10261061A1 (de) 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
JP2004217596A (ja) 2003-01-17 2004-08-05 Taisho Pharmaceut Co Ltd 点眼剤組成物
US20040162273A1 (en) 2003-01-23 2004-08-19 The Procter & Gamble Company Powder pharmaceutical compositions
JP2004300138A (ja) 2003-03-18 2004-10-28 Takeda Chem Ind Ltd 安定化された経口固形製剤
WO2004084637A1 (en) 2003-03-24 2004-10-07 Council Of Scientific And Industrial Research A high fibre biscuit composition and a process for preparing the same
JP4473539B2 (ja) 2003-08-12 2010-06-02 エスエス製薬株式会社 医薬組成物
US7118772B2 (en) 2003-09-18 2006-10-10 General Mills, Inc. Inulin infused fruit and method of preparation
DE10358213A1 (de) 2003-12-12 2005-07-28 Clariant Gmbh Polyethylenglykol und dessen Herstellung
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
JP2005247802A (ja) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd 点眼剤
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20060039973A1 (en) 2004-08-19 2006-02-23 Mary Aldritt Effervescent composition including water soluble dietary fiber
US20060148837A1 (en) * 2005-01-04 2006-07-06 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
DE102006030757A1 (de) 2005-07-18 2007-02-01 Carl Zeiss Smt Ag Polarisationsoptimiertes Beleuchtungssystem
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
CA2636061C (en) 2006-01-27 2015-06-02 Cadbury Adams Usa Llc Flavor-enhancing compositions, methods of manufacture, and methods of use
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20080014275A1 (en) 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
US20080069874A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for Prevention and Treatment of Rhinitis
AP2015008704A0 (en) 2013-02-04 2015-09-30 Aft Pharmaceuticals Ltd A combination medicament comprising phenylephrine and paracetamol

Also Published As

Publication number Publication date
CA2650036A1 (en) 2007-11-01
BRPI0710483B1 (pt) 2019-07-30
EP2046289A2 (en) 2009-04-15
CA2650036C (en) 2012-10-23
JP5362549B2 (ja) 2013-12-11
US20070249727A1 (en) 2007-10-25
US11491151B2 (en) 2022-11-08
US12083117B2 (en) 2024-09-10
ES2454967T3 (es) 2014-04-14
US10688089B2 (en) 2020-06-23
PL2046289T3 (pl) 2014-06-30
US20220023236A1 (en) 2022-01-27
CN101631539A (zh) 2010-01-20
AU2007242419B2 (en) 2012-08-30
BRPI0710483B8 (pt) 2021-05-25
US11141415B2 (en) 2021-10-12
AU2007242419A1 (en) 2007-11-01
BRPI0710483A2 (pt) 2011-08-16
US10098873B2 (en) 2018-10-16
US20170100391A1 (en) 2017-04-13
US20200268746A1 (en) 2020-08-27
WO2007122581A3 (en) 2009-07-02
US20220152016A1 (en) 2022-05-19
EP2046289B1 (en) 2014-01-29
MX2008013257A (es) 2009-03-06
WO2007122581A2 (en) 2007-11-01
US20190008851A1 (en) 2019-01-10
JP2009535305A (ja) 2009-10-01

Similar Documents

Publication Publication Date Title
BRPI0710483A8 (pt) composições e kits úteis para o tratamento de doenças respiratórias
NI201000055A (es) 2&#39; - fluoro - 2&#39; - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
EA200901617A1 (ru) Борсодержащие молекулы небольшого размера
BRPI0710485A8 (pt) composições e métodos úteis para tratamento de doenças respiratórias
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
PA8759501A1 (es) Formas cristalinas
BRPI0607279A2 (pt) composição compatìvel com fertilizante
MX384206B (es) Formulaciones de inhibidores de dpp iv
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
BRPI0619357B8 (pt) anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
BRPI0921482A8 (pt) Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
ECSP088884A (es) Compuestos heterociclicos fusionados y su uso como moduladores de mglur5
DE602007008706D1 (de) Herstellung von eslicarbazepin und verwandten verbindungen mittels asymmetrischer hydrierung
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
ECSP099776A (es) Moduladores de la gamma secretasa
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0917593A2 (pt) &#34;processo de preparação de alofanato de um ou mais isocianatos, alofanato, usos de um alofanato, composição de isocianatos polifuncionais tricondensados e uso de uma composição&#34;

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2667 DE 15-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.